• Crinetics entered non-compete agreements on July 6, 2026 with key executives tied to its planned merger with Vertex.
• One-year restrictions apply from the merger closing date, covering work for specified competing businesses in territories where Crinetics operates.
• At closing, cash payments are set at USD 140,000 for CFO Tobin Schilke, USD 30,000 for CSO Stephen Betz, USD 30,000 for CCO Isabel Kalofonos.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-028208), on July 10, 2026, and is solely responsible for the information contained therein.